Access Before Evidence and the Price of FDA's New Drug Authorities

SSRN Electronic Journal
doi 10.2139/ssrn.3346574
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The FDA's Definitions, Designations, and Drug Approvals: Too Daring?

The Lancet Haematology
Hematology
2018English

Inappropriate Obstructions to Access: The FDA's Handling of Plan B

AMA journal of ethics
Health PolicyEthicsHealthIssuesLegal Aspects
2014English

Price Rigidity and Flexibility: New Empirical Evidence

Managerial and Decision Economics
ManagementBusinessInternational ManagementStrategyManagement ScienceInnovationManagement of TechnologyOperations Research
2007English

FDA's Counsel Accused of Being Too Close to Drug Industry

BMJ
2004English

New Evidence on the Price Effects of Cigarette Tax Competition

Public Finance Review
EconomicsEconometricsPublic AdministrationFinance
2015English

New Evidence on State Banking Before the Civil War

2006English

Before and After Studies to Reduce the Gap Between Road Users and Authorities

2013English

Drug Decriminalization and the Price of Illicit Drugs

International Journal of Drug Policy
MedicineHealth Policy
2017English

The Social Determinants of Food Purchasing Practices: Who Chooses Price-Before-Health, Taste-Before-Price or Organic Foods in Australia?

Food and Nutrition Sciences
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy